The unresolved mystery of high-density lipoprotein: time for a paradigm shift?

Enkhmaa, Byambaa; Anuurad, Erdembileg; Berglund, Lars

doi:10.1016/j.trsl.2016.03.004

Cited by 3 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, there is observed a novel mechanism of interaction between HDL particles and infl ammation which involves circulating microparticles (MPs) and microRNAs (miRNAs). A schematic model "HDL on the background of infl uence of MPs and miRNAs" is represented by Figure 1 (11)(12)(13)(14). As a result of these processes the (dys)functionality of HDL projected into the size of HDL particles can be crucial for the pathophysiological basis of atherogenic dyslipidaemia and cholesterol homeostasis.…”

Section: Hdl Cholesterol Versus Hdl Particlesmentioning

confidence: 99%

Would Janus’ view on HDL be useful?

Kasko¹,

Oravec²

2018

BLL

View full text Add to dashboard Cite

Low-density lipoprotein cholesterol (LDL-C) is generally considered to be pro-atherogenic and high-density lipoprotein cholesterol (HDL-C) to be anti-atherogenic. The clinical approach to the diagnostics and treatment of clinical manifestations of atherosclerosis is the examination of the lipid spectrum. In routine clinical practice, the effects of the HDL class are measured only by determining the concentration of HDL cholesterol. It is questionable whether this clinical approach provides sufficient information to evaluate both the overall cardiovascular risk and the effect of hypolipidemic therapy. Recent studies revealed a shift from large to small HDL particles within the HDL family in the state of atherosclerotic cardiovascular diseases (CVD). This trend of lipoprotein constellation seems to be pathognomonic for dysfunctional lipoprotein profile under pathological state of the cardiovascular system. Thus, the diagnostic and therapeutic approach based on "good" cholesterol concept needs remedying (Fig. 1, Ref. 28).

show abstract

Section: Hdl Cholesterol Versus Hdl Particlesmentioning

confidence: 99%

Would Janus’ view on HDL be useful?

Kasko¹,

Oravec²

2018

BLL

View full text Add to dashboard Cite

show abstract

“…The results of recent intervention studies targeting high‐density lipoprotein cholesterol (HDL‐C) were disappointing, forcing to revisit the epidemiological concept and clinical strategies for patients with low HDL‐C and/or inefficient reverse cholesterol transport (RCT) . Thus, negative results from randomized clinical trials, whose aim was to increase HDL‐C, led to renewed interest towards particles' functionality.…”

Section: Introductionmentioning

confidence: 99%

“…The results of recent intervention studies targeting high-density lipoprotein cholesterol (HDL-C) were disappointing, forcing to revisit the epidemiological concept and clinical strategies for patients with low HDL-C and/or inefficient reverse cholesterol transport (RCT). [1][2][3] Thus, negative results from randomized clinical trials, whose aim was to increase HDL-C, led to renewed interest towards particles' functionality. In this case, a single determination of HDL-C merely represents an averaged and static estimate of the cholesterol load of different HDL subclasses and provides little indication pertaining to HDL qualities and RCT extent.…”

Section: Introductionmentioning

confidence: 99%

[HDL‐C/apoA‐I]: A multivessel cardiometabolic risk marker in women with T2DM

Hermans

Valensi

Ahn

et al. 2017

Diabetes Metabolism Res

View full text Add to dashboard Cite

Aims: Although women have higher high-density lipoprotein cholesterol (HDL-C) than have men, their HDL particles are also prone to become small, dense, and dysfunctional in case of type 2 diabetes mellitus (T2DM). To assess the vascular risk related to HDLs of different sizes/densities without direct measurement, we adjusted HDL-C to its main apolipoprotein Results: An adverse cardiometabolic profile characterized QI and QII patients whose HDLs were denser and depleted in apoA-I, whereas QIII patients had HDLs with characteristics closer to those of controls. QIV patients had HDLs of supernormal size/composition and a more favourable phenotype in terms of fat distribution; insulin sensitivity (64% vs 41%), metabolic syndrome, and β-cell function (32% vs 23%); exogenous insulin (44 vs 89 U·d −1 ); and glycaemic control (glycated haemoglobin, 56 vs 61 mmol·mol −1 ), associated with lower prevalence of microvascular/macrovascular complications: all-cause microangiopathy 47% vs 61%; retinopathy 22% vs 34%; all-cause macroangiopathy 19% vs 31%; and coronary artery disease 6% vs 24% (P < .05). Conclusion:[HDL-C/apoA-I] can stratify T2DM women according to metabolic phenotype, macrovascular and coronary damage, β-cell function, microangiopathic risk, and retinopathy. This ratio is a versatile and readily available marker of cardiometabolic status and vascular complications in T2DM women.

show abstract